Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples

Authors
Miller, MD Margot, NA Hertogs, K Larder, B Miller, V
Citation
Md. Miller et al., Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples, NUCLEOS NUC, 20(4-7), 2001, pp. 1025-1028
Citations number
10
Categorie Soggetti
Biochemistry & Biophysics
Journal title
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS
ISSN journal
15257770 → ACNP
Volume
20
Issue
4-7
Year of publication
2001
Pages
1025 - 1028
Database
ISI
SICI code
1525-7770(2001)20:4-7<1025:AAOT(A>2.0.ZU;2-X
Abstract
The presence of the lamivudine-associated M184V RT mutation increases tenof ovir susceptibility in multiple HIV genotypes. Tenofovir is uniquely active against multinucleoside-resistant HIV expressing the Q151M mutation, but s hows reduced susceptibility to the T69S insertion mutations. HIV with commo n forms of zidovudine and lamivudine resistance are susceptible to tenofovi r, corroborating phase II clinical results demonstrating the activity of te nofovir DF in treatment-experienced patients.